IV 沖洗注射器全球市場-2022-2029

市場動態

IV 閃光注射器的創新有望推動市場增長。

雙腔注射器是藥物和設備組合產品，旨在促進輕鬆重構和預定義數量的藥物給藥。當今市場上的許多多流體注射器並不是很受歡迎，因為它們經常注射兩種流體，一種已經預先填充，另一種需要填充藥物的空腔。然而，沒有一種注射器可以同時給藥通常的藥物溶液和隨後的導管清潔，並且它正在變得普遍。新開發的兩室注射器填補了這一市場空白，可以同時填充和供應化學溶液和清潔溶液。此外，這種注射器的使用使護士在輸液過程中更容易進行沖洗，預計將具有縮短準備和給藥時間、減少導管調整次數以及減少與 PIVC 相關的問題等效果。因此，從上述陳述來看，預計將在預測期內推動市場。

與 IV 沖洗注射器相關的並發症預計會阻礙市場增長。

當一個或多個氣泡進入動脈或靜脈並限制血流時，就會發生空氣栓塞。注射器或滴管可能會無意中將空氣注入靜脈。大多數空氣栓塞是良性的，很少或沒有症狀。空氣栓塞通常會自行消退而不會產生不良影響。然而，空氣栓塞非常罕見，很少影響大腦、心臟或肺部。如果發生空氣栓塞，可能會導致心髒病發作、中風和呼吸衰竭。

此外，氯化鈉清潔劑的兩個更嚴重的副作用是體液過多和過敏反應。雖然相對罕見，但兩者都可能致命並增加清洗注射器的召回率。因此，從上述陳述來看，預計市場在預測期內將受到阻礙。

行業分析

IV Flash Syringe Market 根據供應鏈分析、價格分析等各種行業因素對市場進行深入分析。

COVID-19 影響分析

COVID-19 大流行對醫療保健系統和市場產生了積極影響。全球 COVID-19 大流行對藥劑師和護士等醫護人員的心理、情感和身體造成了嚴重影響。此外，臨床工作人員必須穿戴額外的個人防護裝備 (PPE)，由於病毒的傳染性，這可能會限制運動範圍和反應時間。這增加了藥物製備和給藥錯誤的可能性。使用即用型 (RTA) 是減輕醫生負擔和盡量減少複雜藥物製備程序的策略之一。例如，預充式註射器和其他 RTA 項目可以大大提高生產力，同時最大限度地減少錯誤和患者受傷的機會。

與此同時，自 2022 年 3 月 21 日起，美國食品藥品監督管理局 (FDA) 已確定全國短缺含有 0.9% 氯化鈉（鹽水）的預裝靜脈 (IV) 鎖定/沖洗注射器。我知道這一點.由於 COVID-19 公共衛生緊急情況期間需求增加以及供應商供應鏈隨後出現的困難，包括一些預裝鹽水鎖/沖洗注射器的永久停產，預裝 0.9% 氯化鈉靜脈鎖/沖洗注射器的注射器快用完了。因此，從上述陳述來看，預計市場在預測期內將蓬勃發展。

本報告提供對全球 IV 閃光注射器市場約 45 多個市場數據表、40 多個圖表和 160 頁的訪問。

內容

第一章研究方法與範圍

• 調查方法
• 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

• 市場影響因素
  • 驅動程序
    • IV 閃光注射器的創新有望推動市場增長。
  • 限制因素
    • 預計與 IV 閃光注射器相關的並發症會阻礙市場增長。
  • 市場機會
  • 影響分析

第五章行業分析

• 供應鏈分析
• 定價分析

第 6 章 COVID-19 分析

• COVID-19 的市場分析
  • COVID-19 之前的市場情景
  • COVID-19 的當前市場情景
  • COVID-19 後或未來情景
• COVID-19 期間的價格動態
• 供需範圍
• 大流行期間與市場相關的政府舉措
• 製造商的戰略舉措
• 總結

第 7 章按類型

• 生理鹽水滴管
• 肝素 IV 沖洗注射器

第 8 章最終用戶

• 醫院
• 診所
• 門診手術中心
• 其他

第 9 章按地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 意大利
  • 西班牙
  • 其他歐洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 其他亞太地區
• 中東和非洲

第 10 章競爭格局

• 主要發展和戰略
• 公司份額分析
• 產品基準
• 值得關注的重點公司列表

第 11 章公司簡介

• B.Braun Melsungen AG
  • 公司簡介
  • 產品組合和描述
  • 主要亮點
  • 財務摘要
• R. A. Caldwell Co. Inc.
• Becton, Dickinson and Company
• Cardinal Health
• Nipro Corporation
• Aquabiliti
• Medline Industries, LP
• Medefil, Inc.
• Polymedicure
• SteriCare Solutions

第 12 章 IV 沖洗注射器全球市場數據M

Market Overview

IV Flush Syringe Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.7 % during the forecast period (2022-2029).

IV flush syringes are common medical devices used to clear intravenous lines. Saline flushes are generally safe and well tolerated by patients when administered properly. Millions of patients use it daily to clean intravenous lines. This makes it more likely that medications will be completely absorbed, won't mix inside the tube, and that blood there won't clot. Saline IV flush syringes and heparin IV flush syringes are the two types of IV flush syringes.

Market Dynamics

Innovation in the IV flush syringes is expected to drive market growth.

Double-chamber syringes have been created as a medicine and device combo product to make it easier to reconstitute and administer pharmaceuticals in predefined amounts. Since they frequently call for the delivery of two fluids, one flush solution that has already been prefilled and an empty chamber that needs to be filled with medication, many of the currently available syringes sold for the administration of multiple fluids have not been well welcomed. However, no syringe that enables filling both chambers simultaneously, one for ordinary medication administration and the other for a subsequent catheter flush, has acquired broad popularity. A double-chamber syringe is created to cover this market gap and allow for the filling and delivery of medication and flush solution. Moreover, the novel syringe is expected to make it easier for nurses to implement best clinical practices during intravenous medication administration, such as flushing, cutting down on preparation and administration time, reducing the number of catheter adjustments, and lowering PIVC-related problems. Thus, from the above statements, the market is expected to drive in the forecast period.

Complications associated with IV Flush Syringe are expected to hamper the market growth.

An air embolism develops when one or more air bubbles enter an artery or vein and restrict blood flow. A syringe or IV can inadvertently inject air into a vein. The majority of air embolisms are benign, producing very subtle symptoms or none at all. These typically go away on their own without having any negative effects. However, air embolisms are extremely rare and rarely affect the brain, heart, or lungs. If they do, a heart attack, stroke, or respiratory failure could result.

Moreover, fluid overload and an allergic reaction are two more severe side effects of a sodium chloride flush. Despite being relatively uncommon, both can be fatal and increase recalls of flush syringes. Thus, from the above statements, the market is expected to get hampered in the forecast period.

Industry Analysis

The IV flush syringe market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has positively impacted healthcare systems and the market. Health care professionals, such as pharmacists and nurses, have experienced significant psychological, emotional, and physical effects due to the global COVID-19 pandemic. Moreover, clinical workers must wear additional personal protective equipment (PPE) that might restrict their range of motion and reaction time due to the virus's contagious nature. This raises the likelihood of mistakes occurring when medications are prepared and administered. Utilizing ready-to-administer (RTA) medications is one strategy to ease physicians' workload and minimize complicated drug preparation steps. Prefilled syringes and other RTA items, for instance, can significantly improve productivity while minimizing mistakes and possible patient injury.

In contrast, as of March 21, 2022, the U.S. Food and Drug Administration (FDA) is aware that there are shortages of prefilled intravenous (IV) lock/flush syringes that contain 0.9 percent sodium chloride (saline) in the country. Due to a rise in demand during the COVID-19 public health emergency and subsequent vendor supply chain difficulties, including the permanent discontinuation of some prefilled saline lock/flush syringes, there is a shortage of prefilled 0.9 percent sodium chloride IV lock/flush syringes. Thus, from the above statements, the market is expected to boost in the forecast period.

Segment Analysis

Saline IV Flush Syringe segment is expected to hold the largest market share in IV Flush Syringe market

The saline IV flush syringe segment is expected to dominate in 2021. The segment benefits because the hazards of microbial contamination that arise when doses are drawn up at the ward level are eliminated by the use of prefilled saline syringes. Additionally, the chance of incorrect selection is decreased by the completely labeled nature of prefilled syringes. The time saved by nurses is another important issue. Ad hoc preparation of intravenous dosages incurs costs (including disposables and nurse time) that are frequently disregarded but can pile up in a busy ward. According to one study, using prefilled syringes reduced nursing time by 42% compared to using traditional injection systems.

Further, under the NPSA recommendation, Northampton General Hospital introduced prefilled saline syringes early this year as a part of a broader push to reduce the use of heparin flushes. The NPSA Alert 20, Promoting Safer Use of Injectable Medicines, served as the starting point and contained several action items and suggested actions to increase the safety of injectable medications. Therefore, it has increased the demand for saline IV flush syringes. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global IV flush syringe market

In 2021, North America accounted for the highest revenue share. The increasing inpatient admissions for chronic diseases, rising surgical procedures, the high adoption of the IV flush syringe, well-established infrastructure and product launches and acquisitions by the region's key market players are some factors the market is expected to boost in the forecast period. For instance, heart disease is the leading cause of death for both sexes and members of most racial and ethnic groups in the United States. Cardiovascular disease claims one life in the United States every 34 seconds. In the United States, heart disease claimed the lives of almost 697,000 people in 2020, accounting for 1 in 5 fatalities. Patients with heart disease who experience an aggravation must be admitted to the hospital and given special care. The strong demand for these syringes is expected to be influenced by this issue.

Moreover, BD (Becton, Dickinson and Company) announced in October 2021 that it had strengthened the US government's access to safe injection devices by boosting production. The public-private cooperation between BD and the Assistant Secretary for Preparedness and Response at the Department of Health and Human Services (HHS) created the new syringe and needle manufacturing lines (ASPR). Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the IV flush syringe market are B. Braun Melsungen AG, R. A. Caldwell Co. Inc., Becton, Dickinson and Company, Cardinal Health, Nipro Corporation, Aquabiliti, Medline Industries, LP, Medefil, Inc., Polymedicure, SteriCare Solutions.

B. Braun Melsungen AG:

Overview:

B. Braun is a German manufacturer of medical and pharmaceutical devices. The B. Braun product line includes 5,000 items, 95 percent of which are manufactured by the company. The company's product portfolio includes infusion, nutrition, pain therapy products, infusion pumps and systems, surgical instruments, suture materials, hip and knee implants, dialysis equipment and accessories, ostomy, disinfection, and wound care products. The company operates its business through five divisions: hospital care, Aesculap, B. Braun Avitum, out-patient market (OPM) and other sales. B. Braun has a presence in 64 countries and develops products in 18 therapy fields of the healthcare industry.

Product Portfolio:

Omniflush with SwabCap: A standard saline intravenous flush syringe with an integrated SwabCap is called an Omniflush with SwabCap. A SwabCap is a luer access valve cap with a 70% isopropyl alcohol disinfection concentration. For the user's convenience, they are incorporated together. The purpose of SwabCap is to serve as a cover for swab-able Luer access valves, shielding them from potential contamination. The SwabCap is a cleaning disinfectant before line access and a physical barrier to contamination between line accesses. SwabCap will disinfect the valve thirty (30) seconds after application and maintains a disinfected valve surface for up to seven (7) days if not removed.

The global IV flush syringe market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Innovation in the IV flush syringes is expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. Complications associated with IV Flush Syringe are expected to hamper the market growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Supply Chain Analysis
• 5.2. Pricing Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type Segment
• 7.2. Saline IV Flush Syringe*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Heparin IV Flush Syringe

8. By End user

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 8.1.2. Market Attractiveness Index, By End user Segment
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Clinics
• 8.4. Ambulatory Surgical Center
• 8.5. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

10. Competitive Landscape

• 10.1. Key Developments and Strategies
• 10.2. Company Share Analysis
• 10.3. Product Benchmarking
• 10.4. List of Key Companies to Watch

11. Company Profiles

• 11.1. B. Braun Melsungen AG*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. R. A. Caldwell Co. Inc.
• 11.3. Becton, Dickinson and Company
• 11.4. Cardinal Health
• 11.5. Nipro Corporation
• 11.6. Aquabiliti
• 11.7. Medline Industries, LP
• 11.8. Medefil, Inc.
• 11.9. Polymedicure
• 11.10. SteriCare Solutions

LIST NOT EXHAUSTIVE

12. Global IV Flush Syringe Market - DataM

• 12.1. Appendix
• 12.2. About Us and Applications
• 12.3. Contact Us